Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$12.63 - $24.47 $18.9 Million - $36.6 Million
-1,497,000 Reduced 36.29%
2,628,000 $62.1 Million
Q3 2023

Nov 14, 2023

SELL
$10.86 - $17.62 $3 Million - $4.87 Million
-276,292 Reduced 6.28%
4,125,000 $61.5 Million
Q2 2023

Aug 14, 2023

BUY
$7.47 - $10.95 $14,133 - $20,717
1,892 Added 0.04%
4,401,292 $48.2 Million
Q1 2023

May 15, 2023

BUY
$5.88 - $9.59 $22.9 Million - $37.4 Million
3,899,400 Added 779.88%
4,399,400 $38.4 Million
Q2 2022

Aug 15, 2022

SELL
$1.72 - $3.39 $1.72 Million - $3.39 Million
-1,000,000 Reduced 66.67%
500,000 $1.48 Million
Q1 2022

May 16, 2022

BUY
$2.77 - $3.64 $138,500 - $182,000
50,000 Added 3.45%
1,500,000 $4.67 Million
Q3 2020

Nov 16, 2020

SELL
$3.32 - $7.24 $3.49 Million - $7.6 Million
-1,050,000 Reduced 42.0%
1,450,000 $10.5 Million
Q2 2020

Aug 14, 2020

BUY
$1.41 - $4.25 $1.41 Million - $4.25 Million
1,000,000 Added 66.67%
2,500,000 $8.73 Million
Q2 2019

Aug 14, 2019

SELL
$6.05 - $13.66 $5.6 Million - $12.6 Million
-925,000 Reduced 38.14%
1,500,000 $10.7 Million
Q1 2019

May 15, 2019

BUY
$8.16 - $13.42 $2.16 Million - $3.55 Million
264,850 Added 12.26%
2,425,000 $32.2 Million
Q4 2018

Feb 14, 2019

BUY
$6.54 - $11.74 $1.21 Million - $2.17 Million
185,150 Added 9.37%
2,160,150 $17 Million
Q3 2018

Nov 14, 2018

SELL
$10.88 - $14.52 $5.44 Million - $7.26 Million
-500,000 Reduced 20.2%
1,975,000 $21.9 Million
Q2 2018

Aug 14, 2018

SELL
$10.66 - $14.38 $10.7 Million - $14.4 Million
-1,000,000 Reduced 28.78%
2,475,000 $33.2 Million
Q1 2018

May 15, 2018

BUY
$9.0 - $15.16 $1.76 Million - $2.96 Million
195,474 Added 5.96%
3,475,000 $45.1 Million
Q4 2017

Feb 14, 2018

BUY
$7.67 - $9.31 $1.57 Million - $1.9 Million
204,526 Added 6.65%
3,279,526 $30.2 Million
Q3 2017

Nov 14, 2017

BUY
$5.95 - $8.26 $18.3 Million - $25.4 Million
3,075,000
3,075,000 $24.8 Million

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.